Clinical trials
Tumor clinical trials
Below are recruiting tumor clinical trials, each written for real people, not researchers. We’re tracking 3,414 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06428331RecruitingPhase 1
Study of SKB518 for advanced solid tumors
This trial tests a new drug called SKB518 for people with advanced solid tumors that have stopped responding to standard treatments or cannot receive them. The goal is to see if SKB518 can help shrink or control the tumor.
Shanghai, ChinaAges 18 years+ - NCT07251166RecruitingPhase 1
Safety study of GenSci140 for advanced solid tumors
This trial tests a new drug, GenSci140, for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and how well it works.
Shenyang, LiaoningAges 18–75 - NCT06414460RecruitingPhase 1/Phase 2
ISM3412 for advanced solid tumors with MTAP deletion
This study tests a new oral drug called ISM3412 for people with advanced solid tumors that have a specific genetic change (MTAP deletion). The goal is to see if the drug can shrink tumors or slow their growth.
Denver, ColoradoAges 18 years+ - NCT06234098RecruitingPhase 1/Phase 2
Study of a new drug for advanced solid tumors
This trial tests a new drug called AT-1965 for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it is safe and if it can shrink tumors.
Scottsdale, ArizonaAges 18 years+ - NCT07021534RecruitingPhase 1
CAR-NK and CAR-T cells for cancer with liver spread
This trial tests a new treatment that uses special immune cells (CAR-NK and CAR-T cells) given directly into the liver artery, then through a vein, to fight advanced solid tumors that have spread to the liver. It is for people who have already tried standard treatments and need new options.
Hangzhou, ZhejiangAges 18–75 - NCT07229898RecruitingPhase 1
GEN-725 tablets for advanced solid tumors
This trial tests a new tablet called GEN-725 for people with advanced solid tumors that have stopped responding to standard treatments or cannot tolerate them. It aims to see if the drug is safe and how it affects the body, and may be an option if you've had prior treatment with PD-1/PD-L1 inhibitors that stopped working at least 6 months ago.
HarbinAges 18–75 - NCT06823609RecruitingPhase 1
Study of QLS-1304 for advanced solid tumors
This trial tests an experimental drug, QLS-1304, for people with advanced solid tumors that have stopped responding to standard treatment. The goal is to see if the drug is safe and effective.
ShanghaiAges 18 years+ - NCT06490068RecruitingPhase 2
LTC004 with toripalimab for immunotherapy-resistant solid tumors
This trial tests a new combination of two drugs (LTC004 and toripalimab) for people with advanced solid tumors that have stopped responding to standard immunotherapy. It aims to see if this combination can help when immunotherapy alone no longer works.
BeijingAges 18–75 - NCT06512116RecruitingPhase 1
Testing SIBP-A17 for advanced solid tumors with HER2
This trial tests a new drug called SIBP-A17 for advanced solid tumors that have not responded to other treatments. It focuses on tumors that have a protein called HER2, and the goal is to see if the drug is safe and effective.
Beijing, Beijing MunicipalityAges 18–75 - NCT06380309RecruitingEarly Phase 1
Study of experimental drug IDOV-SAFE for advanced digestive cancers
This trial tests an investigational drug for people with advanced digestive system cancers (like colorectal, stomach, or liver cancer) that have stopped responding to standard treatments. The goal is to see if the drug is safe and helps control the cancer.
BeijingAges 18–75 - NCT06515626RecruitingEarly Phase 1
Modified t cells for multiple cancers
This trial tests a personalized cell therapy where your own immune cells are collected, modified to better attack cancer, and then returned to you. It is for people with various solid tumors and lymphomas whose cancer cells have specific markers.
Zhengzhou, HenanAges 18–75 - NCT04064359RecruitingPhase 1
Safety study of OBT076 for certain CD205+ solid tumors
This Phase 1 trial tests the safety of a new drug called OBT076 and looks for early signs it can help people with certain advanced (recurrent or metastatic) solid tumors that have a specific marker called CD205. You may be eligible if standard treatments are not available or no longer work, and your cancer meets lab and scan requirements.
Phoenix, ArizonaAges 18 years+ - NCT07030959RecruitingPhase 1
AUBE00 for advanced solid tumors with KRAS mutation
This trial tests an experimental drug called AUBE00 for people with solid tumors that have a KRAS mutation, after other treatments have failed. It aims to see if the drug is safe and can shrink tumors.
Grand Rapids, MichiganAges 18 years+ - NCT07192107RecruitingPhase 1/Phase 2
Study of MHB042C for advanced solid tumors
This trial tests a new drug called MHB042C for people with advanced solid tumors that have stopped responding to other treatments. It aims to see if the drug is safe and effective.
Guangzhou, GuangdongAges 18 years+ - NCT06349811RecruitingPhase 1
Study of BL-M05D1 for advanced solid tumors
This study tests a new drug called BL-M05D1 for people with advanced or metastatic solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective.
Beijing, Beijing MunicipalityAges 18–75 - NCT05434234RecruitingPhase 1/Phase 2
Study drug YL201 for advanced solid tumors
This trial tests YL201 in people with advanced (late-stage) solid cancers when usual treatments don’t work or can’t be tolerated. The study looks at how the treatment is given, how safe it is, and how well it can shrink tumors.
Fair Oaks, CaliforniaAges 18 years+ - NCT06342336RecruitingPhase 1
HS-IT101 injection for advanced solid tumors
This trial tests an experimental cell therapy (HS-IT101) for people with advanced solid tumors that have not responded to standard treatments. It uses immune cells from your own tumor to fight cancer, and researchers want to see if it is safe and effective.
Beijing, Beijing MunicipalityAges 3 weeks–2 months - NCT07147348RecruitingPhase 1/Phase 2
BNT3212 alone or with BNT327 for advanced solid tumors
This trial tests a new drug called BNT3212, either alone or combined with BNT327, in people with advanced solid tumors that have not gotten better with standard treatments. The goal is to find safe doses and see if the drugs can shrink tumors or slow their growth.
AdelaideAges 18 years+ - NCT05423977Enrolling by invitationPhase 1
Testing ZV0203 for HER2-positive advanced solid tumors
This Phase 1 study tests ZV0203, a new investigational treatment, in people with HER2-positive advanced or metastatic solid tumors that cannot be removed and have not responded to standard treatment. The goal is to find a safe dose and see how the disease responds.
Zigong, ShandongAges 18 years+ - NCT06336707RecruitingPhase 1
HS-20089 combination for advanced solid tumors
This trial tests a new combination treatment called HS-20089 for people with advanced solid tumors. The goal is to see if it is safe and how well it works against cancer that has not responded to other treatments.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05940896RecruitingPhase 1
HER2-targeted drug with radiation for non-surgical solid cancers
This Phase 1 study tests a HER2-targeted antibody drug (RC48-ADC) given with radiation in people with locally advanced solid tumors that cannot be removed by surgery. It aims to find a safe way to use the treatment and see how well it works in cancers that have HER2 protein on their cells.
Jinan, ShandongAges 18 years+ - NCT07124117RecruitingPhase 1/Phase 2
Study of OBI-902 for advanced solid tumors
This trial tests an experimental drug called OBI-902 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if OBI-902 can help shrink or control the cancer.
La Jolla, CaliforniaAges 18 years+ - NCT07328217RecruitingPhase 1/Phase 2
Study of GW5282 for advanced solid tumors
This trial tests a new oral drug, GW5282, for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if this drug can shrink tumors or stop them from growing.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07050459RecruitingPhase 1
Study of SIM0686 for advanced solid tumors
This trial tests a new drug (SIM0686) in people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and how it affects tumors that have a specific protein called FGFR2b on their surface.
Beijing, Beijing MunicipalityAges 18 years+
Hear when a new Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for tumor?
- Yes. Clin2 currently lists 3,414 recruiting tumor studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a tumor trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a tumor trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.